Skip to search formSkip to main contentSkip to account menu

Lantus

Known as: Lantus Solostar, Solostar, Lantus 
National Institutes of Health

Related topics

Related topics

2 relations
3 ML Insulin Glargine 100 UNT/ML Pen Injector [Lantus]

Broader (1)

Insulin Glargine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels
LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products with identical amino acid sequences. This was a phase 1… 
Highly Cited
2015
Highly Cited
2015
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine… 
2011
2011
Ease of use and preference of a new versus widely available prefilled insulin pen assessed by people with diabetes, physicians and nurses
Objective: FlexTouch (FT; Novo Nordisk A/S, Bagsvaerd, Denmark) is a new prefilled insulin pen that has no push-button extension… 
Review
2011
Review
2011
A Pan-European and Canadian Prospective Survey to Evaluate Patient Satisfaction with the SoloSTAR Insulin Injection Device in Type 1 and Type 2 Diabetes
Objective: This study evaluated patient satisfaction with SoloSTAR® (sanofi-aventis), a prefilled insulin pen device for… 
2011
2011
Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens
This study was performed to compare the insulin glargine produced by two different manufacturers. The study determines the… 
2009
2009
Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin…
OBJECTIVE To discuss the design and baseline data of the Lantus (sanofi-aventis, Paris, France) versus Levemir (Novo Nordisk A/S… 
2008
2008
Evaluation of the injection force dynamics of a modified prefilled insulin pen
Objective: A modified version of the widely used pen FlexPen® (FP), called Next Generation FlexPen® (NGFP), has been designed to… 
2008
2008
Insulin delivery with FlexPen®: dose accuracy, patient preference and adherence
The introduction of insulin pens has helped improve adherence in Type 1 or 2 diabetes, and reduce inaccurate dosing, fear of… 
2007
2007
Intention to treat--initiating insulin and the 4-T study.
The normalization of glucose levels plays an important role in protecting patients with diabetes from complications such as… 
2002
2002
Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: a case report.
The insulin analog insulin glargine has a pharmacodynamic profile described as peakless and of longer duration than human NPH… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)